High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. - Wikidata - awgldk - TriplyDB

High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.

High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.

http://www.wikidata.org/entity/Q33998443

about

Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS.A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy.Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys.A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients.Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.Nucleoside analogs: ready to enter the era of precision medicine?Individualized conditioning regimes in cord blood transplantation: Towards improved and predictable safety and efficacy.Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors.Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation.Pretransplant conditioning with fludarabine and IV busulfan, reduced toxicity and increased safety without compromising antitumor efficacy and overall treatment effect?Hematopoietic Stem Cell Transplantation for Severe Combined Immunodeficiency.

P2860

Q33949932-95A9747B-D7F7-4666-821C-F22EC94B59E2 Q34480145-F60049C4-5061-4AF5-93BC-35D5A7BF1F76 Q34807259-6277A66E-66F8-4608-8F50-13A4820C5578 Q35811940-3C5C846E-680E-40F3-8912-2B174A47E9C5 Q35939500-692BA066-74BB-4D5B-831D-D3A62891B3F4 Q37206443-01988DD9-8B17-4B69-883A-B2213677B06D Q38374457-DCF5927C-96CE-4FBD-A097-468FA2D0C9B0 Q38842938-ABDA25DC-19F2-46F2-86DF-95FCA18E293E Q38897538-52FB9310-5DBF-4ECD-8D5E-6951BBC64EEF Q40791419-49EAFE41-573B-46A0-A74E-37221FE28A16 Q42882109-8D123C0D-B3E1-435E-87BA-1B51B42654FE Q43418954-62173F88-B711-4616-A6EF-46DD71A9B1A5 Q54179395-367D4017-6BA2-4DC4-BDDD-F5C3A19CC340 Q55334301-6EDC78F8-0327-43CC-9081-9438C8688F38

P2860

High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.

http://www.wikidata.org/entity/Q33998443

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

High fludarabine exposure and ...... opoietic cell transplantation.

@ast

High fludarabine exposure and ...... opoietic cell transplantation.

@en

type

label

High fludarabine exposure and ...... opoietic cell transplantation.

@ast

High fludarabine exposure and ...... opoietic cell transplantation.

@en

prefLabel

High fludarabine exposure and ...... opoietic cell transplantation.

@ast

High fludarabine exposure and ...... opoietic cell transplantation.

@en

P1433

Q33998443-6FEE8036-0CA6-4C50-B86A-807CDF212E57

P1476

Q33998443-0B7F1E0E-19EB-4117-A5B3-987C55C80082

P2093

Q33998443-0962185C-11F9-4E65-BBFE-F24D297219C4

Q33998443-2C2BC304-637B-4E09-A1E6-1E7AB2C3BB53

Q33998443-35EB227F-4E64-4078-91BD-1CC2811657F5

Q33998443-57F9729D-7DCF-405E-ADFF-9B2E3130FDAF

Q33998443-66B8B648-63D5-436D-B093-0209F330D6FE

Q33998443-69E8BA59-216C-4E9E-BA51-75DD4E916817

Q33998443-721181BA-1527-4E02-ABFA-FF7E786DE20F

Q33998443-95C29976-240B-43E3-ACC7-BD403B738561

Q33998443-F2D28539-4D68-43D5-B83A-8E267AB08DA0

P2860

Q33998443-0B1B20BB-E0FF-43BB-98BA-382289718315

Q33998443-283ACFFD-E9FE-4280-BA02-3179B896C9BA

Q33998443-296848C0-6866-4749-BABE-C44F1D6DA50A

Q33998443-2C2DEDD7-0774-471C-837B-D94B2FD45AB0

Q33998443-2F86BF30-D11B-483F-8831-0A6AE9177988

Q33998443-3B70C019-1442-469B-9650-5C48EEBCF48B

Q33998443-3DACF959-493D-4F08-8BDB-D0FF94891315

Q33998443-3E729C71-4889-4583-9191-0CE894589696

Q33998443-493050C8-FEAD-4958-AD60-145510B0F916

Q33998443-52F22B75-3CF0-47A1-A9F9-FB76C6F9F4DB

P2888

Q33998443-186764B6-DDFF-422E-8B2C-01BD8AA56183

P304

Q33998443-1BE29414-28C0-456F-B2CC-A945EAEE3FD4

P31

Q33998443-D8AB46BC-482F-4CBE-A2C2-BE6A0B3C2671

P356

Q33998443-5A7AA9F5-D2C7-4A57-B65D-7D8C8E8A63FE

P407

Q33998443-F95F6D40-0FE6-44B3-8A17-6A81147C08F8

P433

Q33998443-FD4506C3-846A-4165-8E17-B8353966D52C

P478

Q33998443-8AA1E356-1911-49D5-A424-CAA1B69E74A9

P50

Q33998443-05C48D0E-6BE6-45CD-971E-0978CE319A67

P577

Q33998443-307C1E11-8307-4154-82A8-2A2B9673181A

P5875

Q33998443-C041F322-B5FE-41BF-B82E-AF41A3193281

P6179

Q33998443-C31A0257-5CE9-4BC3-BCA1-51ABC6E45499

P698

Q33998443-C3632579-2322-44AF-B83E-5FEB56B7638D

P932

Q33998443-A8242FF4-5203-4B6D-B2E4-F443AAF4CC07

P356

P1433

Bone Marrow Transplantation

P1476

High fludarabine exposure and ...... topoietic cell transplantation

@en

P2093

C G Brunstein

http://www.w3.org/2001/XMLSchema#string

D J Weisdorf

http://www.w3.org/2001/XMLSchema#string

J E Wagner

http://www.w3.org/2001/XMLSchema#string

J R Long-Boyle

http://www.w3.org/2001/XMLSchema#string

J Rogosheske

http://www.w3.org/2001/XMLSchema#string

K G Green

http://www.w3.org/2001/XMLSchema#string

P A Jacobson

http://www.w3.org/2001/XMLSchema#string

P B McGlave

http://www.w3.org/2001/XMLSchema#string

Q Cao

http://www.w3.org/2001/XMLSchema#string

P2860

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Prediction of creatinine clearance from serum creatinine

Cyclosporine neurotoxicity: a review.

Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite.

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.

Cellular and clinical pharmacology of fludarabine.

Progressive multifocal leukoencephalopathy with detection of JC virus in a patient with chronic lymphocytic leukemia parallel to onset of fludarabine therapy.

Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.

Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders.

Metabolism and action of fludarabine phosphate.

P2888

P304

20-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2010.53

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey S. Miller

P577

2010-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43100177

http://www.w3.org/2001/XMLSchema#string

P6179

1041656111

http://www.w3.org/2001/XMLSchema#string

P698

20383215

http://www.w3.org/2001/XMLSchema#string

P932

2904846

http://www.w3.org/2001/XMLSchema#string